Abstract Great progress has been made in utilizing immune checkpoint blockade (ICB) for the treatment of non-small-cell lung cancer (NSCLC). Therapies targeting programmed cell death protein 1 (PD-1) and its ligand PD-L1. expressed on tumor cells. have demonstrated potential in improving patient survival rates. https://yeswellneses.shop/product-category/mobility-aids/